+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID06468774

Biomarkers and Quality of Life in Adults with Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome Compared to Other Intestinal Conditions and Healthy Adults

Led by Oslo University Hospital · Updated on 2025-07-30

180

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating plasma Alpha glutathione S transferase Alpha GST levels in patients with chronic mesenteric ischemia CMI and median arcuate ligament syndrome MALS, conditions that cause abdominal pain and weight loss. The study compares these levels to those in patients with Morbus Crohn, gallstone disease, and healthy individuals, aiming to find better biomarkers for intestinal ischemia and assess changes in quality of life. This observational study includes patients diagnosed by imaging and healthy controls, exploring Alpha GST alongside other potential markers like intestinal fatty acid binding protein, citrulline, and ischemia-modified albumin. Participants receive different treatments based on their condition patients with MALS undergo laparoscopic surgery to release the celiac artery, while those with CMI receive open bypass surgery or endovascular treatment with PTA and stenting. Control groups include patients scheduled for gallbladder removal or with Crohns disease, as well as healthy blood donors. Blood samples are collected at inclusion and three months later, with imaging used to confirm diagnoses and exclude conditions in controls. Participants complete questionnaires about symptoms and quality of life, including the EuroQol 5D EQ-5D, at various points up to 10 years after treatment. Follow-up visits include clinical assessments and duplex ultrasound to monitor outcomes. The study also collects data on treatment complications and costs to analyze quality-adjusted life years and cost-utility. The main outcome measured is plasma Alpha GST levels at three months, with long-term tracking of clinical outcomes and quality of life up to 10 years.

CONDITIONS

Brief Title

Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia

Research Team

S

Syed Sajid Hussain Kazmi, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here